Clinical Trial Update: Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tarlatamab in DLL3-expressing tumors, including neuroendocrine neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: DLL3-expressing Tumors, Advanced Tumors | Phase 2 | Status: RECRUITING